Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC) of the pancreas represents a rare subtype of pancreatic ductal adenocarcinoma (PDAC). Despite a distinct morphology and specific clinical behavior, UCOGCs exhibit unexpected similarities in regard to DNA mutational profiles with conventional PDAC. Treating pancreatic ductal adenocarcinoma is particularly challenging, with limited prospects for cure. As with many other malignant neoplasms, the exploration of microRNAs (miRNAs, miRs) in regulating the biological characteristics of pancreatic cancer is undergoing extensive investigation to enhance tumor diagnostics and unveil the therapeutic possibilities. Herein, we evaluated the expression of miR-21, -96, -148a, -155, -196a, -210, and -217 in UCOGCs and poorly differentiated (grade 3, G3) PDACs. The expression of miR-21, miR-155, and miR-210 in both UCOGCs and G3 PDACs was significantly upregulated compared to the levels in normal tissue, while the levels of miR-148a and miR-217 were downregulated. We did not find any significant differences between cancerous and normal tissues for the expression of miR-96 and miR-196a in G3 PDACs, whereas miR-196a was slightly, but significantly, downregulated in UCOGCs. On the other hand, we have not observed significant differences in the expression of the majority of miRNAs between UCOGC and G3 PDAC, with the exception of miR-155. UCOGC samples demonstrated lower mean levels of miR-155 in comparison with those in G3 PDACs.

Clinical and Transplant Pathology Centre Institute for Clinical and Experimental Medicine 140 00 Prague Czech Republic

Department of Medical Biophysics and Medical Informatics 3rd Faculty of Medicine Charles University 100 00 Prague Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University University Hospital Královské Vinohrady 100 00 Prague Czech Republic

Department of Surgery 3rd Faculty of Medicine Charles University University Hospital Královské Vinohrady 100 00 Prague Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University General University Hospital 100 00 Prague Czech Republic

Zobrazit více v PubMed

Hruban R.H., Adsay N.V., Esposito I., Fukushima N., Furukawa T., Klöppel G., Maitra A., Notohara K., Offerhaus G.J.A., Ohike N., et al. WHO Classification of Tumours Editorial Board. Digestive System Tumours. International Agency for Research on Cancer; Lyon, France: 2019. Pancreatic ductal adenocarcinoma; pp. 329–330.

Muraki T., Reid M.D., Basturk O., Jang K.T., Bedolla G., Bagci P., Mittal P., Memis B., Katabi N., Bandyopadhyay S., et al. Undifferentiated Carcinoma with Osteoclastic Giant Cells of the Pancreas: Clinicopathologic Analysis of 38 Cases Highlights a More Protracted Clinical Course than Currently Appreciated. Am. J. Surg. Pathol. 2016;40:1203–1216. doi: 10.1097/PAS.0000000000000689. PubMed DOI PMC

Sommers S.C., Meissner W.A. Unusual Carcinomas of the Pancreas. AMA Arch. Pathol. 1954;58:101–111. PubMed

Rosai J. Carcinoma of Pancreas Simulating Giant Cell Tumor of Bone. Electron-Microscopic Evidence of Its Acinar Cell Origin. Cancer. 1968;22:333–344. doi: 10.1002/1097-0142(196808)22:2<333::aid-cncr2820220210>3.0.co;2-a. PubMed DOI

Luchini C., Cros J., Pea A., Pilati C., Veronese N., Rusev B., Capelli P., Mafficini A., Nottegar A., Brosens L.A.A., et al. PD-1, PD-L1, and CD163 in Pancreatic Undifferentiated Carcinoma with Osteoclast-like Giant Cells: Expression Patterns and Clinical Implications. Hum. Pathol. 2018;81:157–165. doi: 10.1016/j.humpath.2018.07.006. PubMed DOI

Bazzichetto C., Luchini C., Conciatori F., Vaccaro V., Di Cello I., Mattiolo P., Falcone I., Ferretti G., Scarpa A., Cognetti F., et al. Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. Int. J. Mol. Sci. 2020;21:8841. doi: 10.3390/ijms21228841. PubMed DOI PMC

Mugaanyi J., Lu C., Huang J., Lu C. Undifferentiated Pancreatic Carcinomas, Clinical Features and Therapeutic Options: What We Know. Cancers. 2022;14:6102. doi: 10.3390/cancers14246102. PubMed DOI PMC

Hrudka J., Kalinová M., Ciprová V., Moravcová J., Dvořák R., Matěj R. Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Molecular Genetic Analysis of 13 Cases. Int. J. Mol. Sci. 2024;25:3285. doi: 10.3390/ijms25063285. PubMed DOI PMC

Ali Syeda Z., Langden S.S.S., Munkhzul C., Lee M., Song S.J. Regulatory Mechanism of MicroRNA Expression in Cancer. Int. J. Mol. Sci. 2020;21:1723. doi: 10.3390/ijms21051723. PubMed DOI PMC

Shang R., Lee S., Senavirathne G., Lai E.C. microRNAs in Action: Biogenesis, Function and Regulation. Nat. Rev. Genet. 2023;24:816–833. doi: 10.1038/s41576-023-00611-y. PubMed DOI PMC

O’Brien J., Hayder H., Zayed Y., Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol. 2018;9:402. doi: 10.3389/fendo.2018.00402. PubMed DOI PMC

Sassen S., Miska E.A., Caldas C. MicroRNA—Implications for Cancer. Virchows Archiv. 2008;452:1–10. doi: 10.1007/s00428-007-0532-2. PubMed DOI PMC

Iorio M.V., Croce C.M. MicroRNA Dysregulation in Cancer: Diagnostics, Monitoring and Therapeutics. A Comprehensive Review. EMBO Mol. Med. 2012;4:143–159. doi: 10.1002/emmm.201100209. PubMed DOI PMC

Moriyama T., Ohuchida K., Mizumoto K., Yu J., Sato N., Nabae T., Takahata S., Toma H., Nagai E., Tanaka M. MicroRNA-21 Modulates Biological Functions of Pancreatic Cancer Cells Including Their Proliferation, Invasion, and Chemoresistance. Mol. Cancer Ther. 2009;8:1067–1074. doi: 10.1158/1535-7163.MCT-08-0592. PubMed DOI

Hu G., Tao F., Wang W., Ji K. Prognostic Value of microRNA-21 in Pancreatic Ductal Adenocarcinoma: A Meta-Analysis. World J. Surg. Oncol. 2016;14:82. doi: 10.1186/s12957-016-0842-4. PubMed DOI PMC

Daoud A.Z., Mulholland E.J., Cole G., McCarthy H.O. MicroRNAs in Pancreatic Cancer: Biomarkers, Prognostic, and Therapeutic Modulators. BMC Cancer. 2019;19:1130. doi: 10.1186/s12885-019-6284-y. PubMed DOI PMC

Szabo A., Gurlich R., Liberko M., Soumarova R., Vernerova Z., Mandys V., Popov A. Expression of Selected microRNAs in Pancreatic Ductal Adenocarcinoma: Is There a Relation to Tumor Morphology, Progression and Patient’s Outcome? Neoplasma. 2020;67:1170–1181. doi: 10.4149/neo_2020_200123N87. PubMed DOI

Popov A., Mandys V. Senescence-Associated miRNAs and Their Role in Pancreatic Cancer. Pathol. Oncol. Res. 2022;28:1610156. doi: 10.3389/pore.2022.1610156. PubMed DOI PMC

Prinz C., Fehring L., Frese R. MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions. Cells. 2022;11:2374. doi: 10.3390/cells11152374. PubMed DOI PMC

Shenouda S.K., Alahari S.K. MicroRNA Function in Cancer: Oncogene or a Tumor Suppressor? Cancer Metastasis Rev. 2009;28:369–378. doi: 10.1007/s10555-009-9188-5. PubMed DOI

Zhang B., Pan X., Cobb G., Anderson T. microRNAs as Oncogenes and Tumor Suppressors. Dev. Biol. 2007;302:1–12. doi: 10.1016/j.ydbio.2006.08.028. PubMed DOI

Eun J.L., Gusev Y., Jiang J., Nuovo G.J., Lerner M.R., Frankel W.L., Morgan D.L., Postier R.G., Brackett D.J., Schmittgen T.D. Expression Profiling Identifies microRNA Signature in Pancreatic Cancer. Int. J. Cancer. 2007;120:1046–1054. doi: 10.1002/ijc.22394. PubMed DOI PMC

Zhang Y., Li M., Wang H., Fisher W.E., Lin P.H., Yao Q., Chen C. Profiling of 95 MicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Real-Time PCR Analysis. World J. Surg. 2009;33:698–709. doi: 10.1109/SPAWC.2012.6292881. PubMed DOI PMC

Negoi I., Hostiuc S., Sartelli M., Negoi R.I., Beuran M. MicroRNA-21 as a Prognostic Biomarker in Patients with Pancreatic Cancer—A Systematic Review and Meta-Analysis. Am. J. Surg. 2017;214:515–524. doi: 10.1016/j.amjsurg.2017.03.049. PubMed DOI

Jamieson N.B., Morran D.C., Morton J.P., Ali A., Dickson E.J., Carter C.R., Sansom O.J., Evans T.R.J., McKay C.J., Oien K.A. MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res. 2012;18:534–545. doi: 10.1158/1078-0432.CCR-11-0679. PubMed DOI

Kong X., Du Y., Wang G., Gao J., Gong Y., Li L., Zhang Z., Zhu J., Jing Q., Qin Y., et al. Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis. Dig. Dis. Sci. 2011;56:602–609. doi: 10.1007/s10620-010-1285-3. PubMed DOI

Papaconstantinou I.G., Manta A., Gazouli M., Lyberopoulou A., Lykoudis P.M., Polymeneas G., Voros D. Expression of microRNAs in Patients with Pancreatic Cancer and Its Prognostic Significance. Pancreas. 2013;42:67–71. doi: 10.1097/MPA.0b013e3182592ba7. PubMed DOI

Bloomston M., Frankel W.L., Petrocca F., Volinia S., Alder H., Hagan J.P., Liu C.G., Bhatt D., Taccioli C., Croce C.M. MicroRNA Expression Patterns to Differentiate Pancreatic Adenocarcinoma from Normal Pancreas and Chronic Pancreatitis. JAMA. 2007;297:1901–1908. doi: 10.1001/jama.297.17.1901. PubMed DOI

Hong T.H., Park I.Y. MicroRNA Expression Profiling of Diagnostic Needle Aspirates from Surgical Pancreatic Cancer Specimens. Ann. Surg. Treat. Res. 2014;87:290. doi: 10.4174/astr.2014.87.6.290. PubMed DOI PMC

Wang J., Chen J., Chang P., LeBlanc A., Li D., Abbruzzesse J.L., Frazier M.L., Killary A.M., Sen S. MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease. Cancer Prev. Res. 2009;2:807–813. doi: 10.1158/1940-6207.CAPR-09-0094. PubMed DOI PMC

Greither T., Grochola L.F., Udelnow A., Lautenschläger C., Würl P., Taubert H. Elevated Expression of microRNAs 155, 203, 210 and 222 in Pancreatic Tumors Is Associated with Poorer Survival. Int. J. Cancer. 2010;126:73–80. doi: 10.1002/ijc.24687. PubMed DOI

Delpu Y., Lulka H., Sicard F., Saint-Laurent N., Lopez F., Hanoun N., Buscail L., Cordelier P., Torrisani J. The Rescue of miR-148a Expression in Pancreatic Cancer: An Inappropriate Therapeutic Tool. PLoS ONE. 2013;8:e55513. doi: 10.1371/journal.pone.0055513. PubMed DOI PMC

Feng J., Yu J., Pan X., Li Z., Chen Z., Zhang W., Wang B., Yang L., Xu H., Zhang G., et al. HERG1 Functions as an Oncogene in Pancreatic Cancer and Is Downregulated by miR-96. Oncotarget. 2014;5:5832–5844. doi: 10.18632/oncotarget.2200. PubMed DOI PMC

Hrudka J., Lawrie K., Waldauf P., Ciprová V., Moravcová J., Matěj R. Negative Prognostic Impact of PD-L1 Expression in Tumor Cells of Undifferentiated (Anaplastic) Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Study of 13 Cases Comparing Ductal Pancreatic Carcinoma and Review of the Literature. Virchows Arch. 2020;477:687–696. doi: 10.1007/s00428-020-02830-8. PubMed DOI

Pfaffl M.W. A New Mathematical Model for Relative Quantification in Real-Time RT-PCR. Nucleic Acids Res. 2001;29:e45. doi: 10.1093/nar/29.9.e45. PubMed DOI PMC

Du Rieu M.C., Torrisani J., Selves J., Al Saati T., Souque A., Dufresne M., Tsongalis G.J., Suriawinata A.A., Carrère N., Buscail L., et al. MicroRNA-21 Is Induced Early in Pancreatic Ductal Adenocarcinoma Precursor Lesions. Clin. Chem. 2010;56:603–612. doi: 10.1373/clinchem.2009.137364. PubMed DOI

Qi L., Bart J., Tan L.P., Platteel I., van der Sluis T., Huitema S., Harms G., Fu L., Hollema H., van den Berg A. Expression of miR-21 and Its Targets (PTEN, PDCD4, TM1) in Flat Epithelial Atypia of the Breast in Relation to Ductal Carcinoma in Situ and Invasive Carcinoma. BMC Cancer. 2009;9:163. doi: 10.1186/1471-2407-9-163. PubMed DOI PMC

Habbe N., Koorstra J.B.M., Mendell J.T., Offerhaus G.J., Ji K.R., Feldmann G., Mullendore M.E., Goggins M.G., Hong S.M., Maitra A. MicroRNA miR-155 Is a Biomarker of Early Pancreatic Neoplasia. Cancer Biol. Ther. 2009;8:340–346. doi: 10.4161/cbt.8.4.7338. PubMed DOI PMC

Gironella M., Seux M., Xie M.-J., Cano C., Tomasini R., Gommeaux J., Garcia S., Nowak J., Yeung M.L., Jeang K.-T., et al. Tumor Protein 53-Induced Nuclear Protein 1 Expression Is Repressed by miR-155, and Its Restoration Inhibits Pancreatic Tumor Development. Proc. Natl. Acad. Sci. USA. 2007;104:16170–16175. doi: 10.1073/pnas.0703942104. PubMed DOI PMC

Yu S., Lu Z., Liu C., Meng Y., Ma Y., Zhao W., Liu J., Yu J., Chen J. miRNA-96 Suppresses KRAS and Functions as a Tumor Suppressor Gene in Pancreatic Cancer. Cancer Res. 2010;70:6015–6025. doi: 10.1158/0008-5472.CAN-09-4531. PubMed DOI

Zhao W.-G., Yu S.-N., Lu Z.-H., Ma Y.-H., Gu Y.-M., Chen J. The miR-217 microRNA Functions as a Potential Tumor Suppressor in Pancreatic Ductal Adenocarcinoma by Targeting KRAS. Carcinogenesis. 2010;31:1726–1733. doi: 10.1093/carcin/bgq160. PubMed DOI

Szafranska A.E., Davison T.S., John J., Cannon T., Sipos B., Maghnouj A., Labourier E., Hahn S.A. MicroRNA Expression Alterations Are Linked to Tumorigenesis and Non-Neoplastic Processes in Pancreatic Ductal Adenocarcinoma. Oncogene. 2007;26:4442–4452. doi: 10.1038/sj.onc.1210228. PubMed DOI

Szafranska A.E., Doleshal M., Edmunds H.S., Gordon S., Luttges J., Munding J.B., Barth R.J., Gutmann E.J., Suriawinata A.A., Pipas J.M., et al. Analysis of microRNAs in Pancreatic Fine-Needle Aspirates Can Classify Benign and Malignant Tissues. Clin. Chem. 2008;54:1716–1724. doi: 10.1373/clinchem.2008.109603. PubMed DOI PMC

Link A., Becker V., Goel A., Wex T., Malfertheiner P. Feasibility of Fecal microRNAs as Novel Biomarkers for Pancreatic Cancer. PLoS ONE. 2012;7:e42933. doi: 10.1371/journal.pone.0042933. PubMed DOI PMC

Molberg K.H., Heffess C., Delgado R., Albores-Saavedra J. Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas and Periampullary Region. Cancer. 1998;82:1279–1287. doi: 10.1002/(SICI)1097-0142(19980401)82:7<1279::AID-CNCR10>3.0.CO;2-3. PubMed DOI

Paal E., Thompson L.D., Frommelt R.A., Przygodzki R.M., Heffess C.S. A Clinicopathologic and Immunohistochemical Study of 35 Anaplastic Carcinomas of the Pancreas with a Review of the Literature. Ann. Diagn. Pathol. 2001;5:129–140. doi: 10.1053/adpa.2001.25404. PubMed DOI

Rosai and Ackerman’s Surgical Pathology—2 Volume Set—11th Edition. [(accessed on 23 May 2023)]. Available online: https://www.elsevier.com/books/rosai-and-ackermans-surgical-pathology-2-volume-set/goldblum/978-0-323-26339-9.

Dworak O., Wittekind C., Koerfgen H.P., Gall F.P. Osteoclastic Giant Cell Tumor of the Pancreas. An Immunohistological Study and Review of the Literature. Pathol. Res. Pract. 1993;189:228–234. doi: 10.1016/S0344-0338(11)80101-9. PubMed DOI

Reid M.D., Muraki T., HooKim K., Memis B., Graham R.P., Allende D., Shi J., Schaeffer D.F., Singh R., Basturk O., et al. Cytologic Features and Clinical Implications of Undifferentiated Carcinoma with Osteoclastic Giant Cells of the Pancreas: An Analysis of 15 Cases. Cancer Cytopathol. 2017;125:563–575. doi: 10.1002/cncy.21859. PubMed DOI

Lehrke H.D., Graham R.P., McWilliams R.R., Lam-Himlin D.M., Smyrk T.C., Jenkins S., Dong H., Zhang L. Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. Am. J. Clin. Pathol. 2017;148:441–449. doi: 10.1093/ajcp/aqx092. PubMed DOI

Besaw R.J., Terra A.R., Malvar G.L., Chapman T.R., Hertan L.M., Schlechter B.L. Durable Response to PD-1 Blockade in a Patient with Metastatic Pancreatic Undifferentiated Carcinoma with Osteoclast-Like Giant Cells. J. Natl. Compr. Canc. Netw. 2021;19:247–252. doi: 10.6004/jnccn.2021.7001. PubMed DOI

Obayashi M., Shibasaki Y., Koakutsu T., Hayashi Y., Shoji T., Hirayama K., Yamazaki M., Takayanagi Y., Shibata H., Nakamura M., et al. Pancreatic Undifferentiated Carcinoma with Osteoclast-like Giant Cells Curatively Resected after Pembrolizumab Therapy for Lung Metastases: A Case Report. BMC Gastroenterol. 2020;20:220. doi: 10.1186/s12876-020-01362-4. PubMed DOI PMC

Mattiolo P., Fiadone G., Paolino G., Chatterjee D., Bernasconi R., Piccoli P., Parolini C., El Aidi M., Sperandio N., Malleo G., et al. Epithelial-Mesenchymal Transition in Undifferentiated Carcinoma of the Pancreas with and without Osteoclast-like Giant Cells. Virchows Arch. 2021;478:319–326. doi: 10.1007/s00428-020-02889-3. PubMed DOI PMC

Sakakida T., Ishikawa T., Doi T., Morita R., Kataoka S., Miyake H., Yamaguchi K., Moriguchi M., Sogame Y., Yasuda H., et al. Genomic Landscape and Clinical Features of Rare Subtypes of Pancreatic Cancer: Analysis with the National Database of Japan. J. Gastroenterol. 2023;58:575–585. doi: 10.1007/s00535-023-01986-9. PubMed DOI PMC

Bergmann F., Moldenhauer G., Herpel E., Gaida M.M., Strobel O., Werner J., Esposito I., Müerköster S.S., Schirmacher P., Kern M.A. Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/Neu in Anaplastic Pancreatic Cancer: Putative Therapeutic Targets? Histopathology. 2010;56:440–448. doi: 10.1111/j.1365-2559.2010.03499.x. PubMed DOI

Wang X., Miao J., Wang S., Shen R., Zhang S., Tian Y., Li M., Zhu D., Yao A., Bao W., et al. Single-Cell RNA-Seq Reveals the Genesis and Heterogeneity of Tumor Microenvironment in Pancreatic Undifferentiated Carcinoma with Osteoclast-like Giant-Cells. Mol. Cancer. 2022;21:133. doi: 10.1186/s12943-022-01596-8. PubMed DOI PMC

Nakata K., Ohuchida K., Mizumoto K., Kayashima T., Ikenaga N., Sakai H., Lin C., Fujita H., Otsuka T., Aishima S., et al. MicroRNA-10b Is Overexpressed in Pancreatic Cancer, Promotes Its Invasiveness, and Correlates with a Poor Prognosis. Surgery. 2011;150:916–922. doi: 10.1016/j.surg.2011.06.017. PubMed DOI

Park J.-K., Lee E.J., Esau C., Schmittgen T.D. Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic Adenocarcinoma. Pancreas. 2009;38:e190. doi: 10.1097/MPA.0b013e3181ba82e1. PubMed DOI

Wang P., Zhu C., Ma M., Chen G., Song M., Zeng Z., Lu W., Yang J., Wen S., Chiao P.J., et al. Micro-RNA-155 Is Induced by K-Ras Oncogenic Signal and Promotes ROS Stress in Pancreatic Cancer. Oncotarget. 2015;6:21148–21158. doi: 10.18632/oncotarget.4125. PubMed DOI PMC

Fasanaro P., D’Alessandra Y., Di Stefano V., Melchionna R., Romani S., Pompilio G., Capogrossi M.C., Martelli F. MicroRNA-210 Modulates Endothelial Cell Response to Hypoxia and Inhibits the Receptor Tyrosine Kinase Ligand Ephrin-A3. J. Biol. Chem. 2008;283:15878–15883. doi: 10.1074/jbc.M800731200. PubMed DOI PMC

Zhang Z., Sun H., Dai H., Walsh R.M., Imakura M., Schelter J., Burchard J., Dai X., Chang A.N., Diaz R.L., et al. MicroRNA miR-210 Modulates Cellular Response to Hypoxia through the MYC Antagonist MNT. Cell Cycle. 2009;8:2756–2768. doi: 10.4161/cc.8.17.9387. PubMed DOI

Huang X., Le Q.-T., Giaccia A.J. MiR-210–Micromanager of the Hypoxia Pathway. Trends Mol. Med. 2010;16:230–237. doi: 10.1016/j.molmed.2010.03.004. PubMed DOI PMC

Buscaglia L.E.B., Li Y. Apoptosis and the Target Genes of microRNA-21. Chin. J. Cancer. 2011;30:371–380. doi: 10.5732/cjc.011.10132. PubMed DOI PMC

Huang C., Li H., Wu W., Jiang T., Qiu Z. Regulation of miR-155 Affects Pancreatic Cancer Cell Invasiveness and Migration by Modulating the STAT3 Signaling Pathway through SOCS1. Oncol. Rep. 2013;30:1223–1230. doi: 10.3892/or.2013.2576. PubMed DOI

Nakamura S., Sadakari Y., Ohtsuka T., Okayama T., Nakashima Y., Gotoh Y., Saeki K., Mori Y., Nakata K., Miyasaka Y., et al. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. Ann. Surg. Oncol. 2019;26:2104–2111. doi: 10.1245/s10434-019-07269-z. PubMed DOI

Huang F., Tang J., Zhuang X., Zhuang Y., Cheng W., Chen W., Yao H., Zhang S. MiR-196a Promotes Pancreatic Cancer Progression by Targeting Nuclear Factor Kappa-B-Inhibitor Alpha. PLoS ONE. 2014;9:e87897. doi: 10.1371/journal.pone.0087897. PubMed DOI PMC

Giovannetti E., Funel N., Peters G.J., Del Chiaro M., Erozenci L.A., Vasile E., Leon L.G., Pollina L.E., Groen A., Falcone A., et al. MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity. Cancer Res. 2010;70:4528–4538. doi: 10.1158/0008-5472.CAN-09-4467. PubMed DOI

Huang X., Zuo J. Emerging Roles of miR-210 and Other Non-Coding RNAs in the Hypoxic Response. Acta Biochim. Et Biophys. Sin. 2014;46:220–232. doi: 10.1093/abbs/gmt141. PubMed DOI

Zhao Q., Chen S., Zhu Z., Yu L., Ren Y., Jiang M., Weng J., Li B. miR-21 Promotes EGF-Induced Pancreatic Cancer Cell Proliferation by Targeting Spry2. Cell Death Dis. 2018;9:1157. doi: 10.1038/s41419-018-1182-9. PubMed DOI PMC

Mok E.T.Y., Chitty J.L., Cox T.R. miRNAs in Pancreatic Cancer Progression and Metastasis. Clin. Exp. Metastasis. 2024 doi: 10.1007/s10585-023-10256-0. PubMed DOI PMC

Wang P., Zhuang L., Zhang J., Fan J., Luo J., Chen H., Wang K., Liu L., Chen Z., Meng Z. The Serum miR-21 Level Serves as a Predictor for the Chemosensitivity of Advanced Pancreatic Cancer, and miR-21 Expression Confers Chemoresistance by Targeting FasL. Mol. Oncol. 2013;7:334. doi: 10.1016/j.molonc.2012.10.011. PubMed DOI PMC

Karásek P., Gablo N., Hlavsa J., Kiss I., Vychytilová-Faltejsková P., Hermanová M., Kala Z., Slabý O., Procházka V. Pre-Operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection. Cancer Genom. Proteom. 2018;15:321–327. doi: 10.21873/cgp.20090. PubMed DOI PMC

Khan K., Cunningham D., Peckitt C., Barton S., Tait D., Hawkins M., Watkins D., Starling N., Rao S., Begum R., et al. miR-21 Expression and Clinical Outcome in Locally Advanced Pancreatic Cancer: Exploratory Analysis of the Pancreatic Cancer Erbitux, Radiotherapy and UFT (PERU) Trial. Oncotarget. 2016;7:12672–12681. doi: 10.18632/oncotarget.7208. PubMed DOI PMC

Nishiwada S., Sho M., Banwait J.K., Yamamura K., Akahori T., Nakamura K., Baba H., Goel A. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases. Gastroenterology. 2020;159:562–574. doi: 10.1053/j.gastro.2020.04.057. PubMed DOI PMC

Mikamori M., Yamada D., Eguchi H., Hasegawa S., Kishimoto T., Tomimaru Y., Asaoka T., Noda T., Wada H., Kawamoto K., et al. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Sci. Rep. 2017;7:42339. doi: 10.1038/srep42339. PubMed DOI PMC

Khan M.A., Zubair H., Srivastava S.K., Singh S., Singh A.P. Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy. Adv. Exp. Med. Biol. 2015;889:71–87. doi: 10.1007/978-3-319-23730-5_5. PubMed DOI PMC

Pang W., Su J., Wang Y., Feng H., Dai X., Yuan Y., Chen X., Yao W. Pancreatic Cancer-Secreted miR-155 Implicates in the Conversion from Normal Fibroblasts to Cancer-Associated Fibroblasts. Cancer Sci. 2015;106:1362–1369. doi: 10.1111/cas.12747. PubMed DOI PMC

Wu Y., Hong Q., Lu F., Zhang Z., Li J., Nie Z., He B. The Diagnostic and Prognostic Value of miR-155 in Cancers: An Updated Meta-Analysis. Mol. Diagn. Ther. 2023;27:283–301. doi: 10.1007/s40291-023-00641-6. PubMed DOI

Kim M.W., Koh H., Kim J.Y., Lee S., Lee H., Kim Y., Hwang H.K., Kim S.I. Tumor-Specific miRNA Signatures in Combination with CA19-9 for Liquid Biopsy-Based Detection of PDAC. Int. J. Mol. Sci. 2021;22:13621. doi: 10.3390/ijms222413621. PubMed DOI PMC

Wang J., Raimondo M., Guha S., Chen J., Diao L., Dong X., Wallace M.B., Killary A.M., Frazier M.L., Woodward T.A., et al. Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. J. Cancer. 2014;5:696–705. doi: 10.7150/jca.10094. PubMed DOI PMC

Lian M., Mortoglou M., Uysal-Onganer P. Impact of Hypoxia-Induced miR-210 on Pancreatic Cancer. Curr. Issues Mol. Biol. 2023;45:9778–9792. doi: 10.3390/cimb45120611. PubMed DOI PMC

Wu G., Ding X., Quan G., Xiong J., Li Q., Li Z., Wang Y. Hypoxia-Induced miR-210 Promotes Endothelial Cell Permeability and Angiogenesis via Exosomes in Pancreatic Ductal Adenocarcinoma. Biochem. Res. Int. 2022;2022:7752277. doi: 10.1155/2022/7752277. PubMed DOI PMC

Yu Q., Xu C., Yuan W., Wang C., Zhao P., Chen L., Ma J. Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively. BioMed Res. Int. 2017;2017:6495867. doi: 10.1155/2017/6495867. PubMed DOI PMC

Wnuk J., Strzelczyk J.K., Gisterek I. Clinical Value of Circulating miRNA in Diagnosis, Prognosis, Screening and Monitoring Therapy of Pancreatic Ductal Adenocarcinoma–A Review of the Literature. Int. J. Mol. Sci. 2023;24:5113. doi: 10.3390/ijms24065113. PubMed DOI PMC

Luthra R., Singh R.R., Luthra M.G., Li Y.X., Hannah C., Romans A.M., Barkoh B.A., Chen S.S., Ensor J., Maru D.M., et al. MicroRNA-196a Targets Annexin A1: A microRNA-Mediated Mechanism of Annexin A1 Downregulation in Cancers. Oncogene. 2008;27:6667–6678. doi: 10.1038/onc.2008.256. PubMed DOI

Lee Y.S., Kim H., Kim H.W., Lee J.-C., Paik K.-H., Kang J., Kim J., Yoon Y.-S., Han H.-S., Sohn I., et al. High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor. Medicine. 2015;94:e2224. doi: 10.1097/MD.0000000000002224. PubMed DOI PMC

Balzeau J., Menezes M.R., Cao S., Hagan J.P. The LIN28/Let-7 Pathway in Cancer. Front. Genet. 2017;8:31. doi: 10.3389/fgene.2017.00031. PubMed DOI PMC

Wang H., Chirshev E., Hojo N., Suzuki T., Bertucci A., Pierce M., Perry C., Wang R., Zink J., Glackin C.A., et al. The Epithelial–Mesenchymal Transcription Factor SNAI1 Represses Transcription of the Tumor Suppressor miRNA Let-7 in Cancer. Cancers. 2021;13:1469. doi: 10.3390/cancers13061469. PubMed DOI PMC

Bhutia Y.D., Hung S.W., Krentz M., Patel D., Lovin D., Manoharan R., Thomson J.M., Govindarajan R. Differential Processing of Let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET Oncoprotein. PLoS ONE. 2013;8:e53436. doi: 10.1371/journal.pone.0053436. PubMed DOI PMC

Idichi T., Seki N., Kurahara H., Fukuhisa H., Toda H., Shimonosono M., Okato A., Arai T., Kita Y., Mataki Y., et al. Molecular Pathogenesis of Pancreatic Ductal Adenocarcinoma: Impact of Passenger Strand of Pre-miR-148a on Gene Regulation. Cancer Sci. 2018;109:2013–2026. doi: 10.1111/cas.13610. PubMed DOI PMC

Hanoun N., Delpu Y., Suriawinata A.A., Bournet B., Bureau C., Selves J., Tsongalis G.J., Dufresne M., Buscail L., Cordelier P., et al. The Silencing of MicroRNA 148a Production by DNA Hypermethylation Is an Early Event in Pancreatic Carcinogenesis. Clin. Chem. 2010;56:1107–1118. doi: 10.1373/clinchem.2010.144709. PubMed DOI

Deng S., Zhu S., Wang B., Li X., Liu Y., Qin Q., Gong Q., Niu Y., Xiang C., Chen J., et al. Chronic Pancreatitis and Pancreatic Cancer Demonstrate Active Epithelial-Mesenchymal Transition Profile, Regulated by miR-217-SIRT1 Pathway. Cancer Lett. 2014;355:184–191. doi: 10.1016/j.canlet.2014.08.007. PubMed DOI

Chang X., Yu C., Li J., Yu S., Chen J. Hsa-miR-96 and Hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms. Int. J. Med. Sci. 2017;14:412–418. doi: 10.7150/ijms.18641. PubMed DOI PMC

Lemberger M., Loewenstein S., Lubezky N., Nizri E., Pasmanik-Chor M., Barazovsky E., Klausner J.M., Lahat G. MicroRNA Profiling of Pancreatic Ductal Adenocarcinoma (PDAC) Reveals Signature Expression Related to Lymph Node Metastasis. Oncotarget. 2019;10:2644–2656. doi: 10.18632/oncotarget.26804. PubMed DOI PMC

Kent O.A., Mullendore M., Wentzel E.A., López-Romero P., Tan A.C., Alvarez H., West K., Ochs M.F., Hidalgo M., Arking D.E., et al. A Resource for Analysis of microRNA Expression and Function in Pancreatic Ductal Adenocarcinoma Cells. Cancer Biol. Ther. 2009;8:2013–2024. doi: 10.4161/cbt.8.21.9685. PubMed DOI PMC

Liu X., Li Y., Li Z., Hou T. miR-155 Promotes Proliferation and Epithelial-Mesenchymal Transition of MCF-7 Cells. Exp. Ther. Med. 2021;21:218. doi: 10.3892/etm.2021.9650. PubMed DOI PMC

Kong W., Yang H., He L., Zhao J., Coppola D., Dalton W.S., Cheng J.Q. MicroRNA-155 Is Regulated by the Transforming Growth Factor Beta/Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA. Mol. Cell. Biol. 2008;28:6773–6784. doi: 10.1128/MCB.00941-08. PubMed DOI PMC

Kong X., Liu F., Gao J. MiR-155 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells through the Activation of PI3K/SGK3/β-Catenin Signaling Pathways. Oncotarget. 2016;7:66051–66060. doi: 10.18632/oncotarget.11800. PubMed DOI PMC

Kulkarni P., Dasgupta P., Hashimoto Y., Shiina M., Shahryari V., Tabatabai Z.L., Yamamura S., Tanaka Y., Saini S., Dahiya R., et al. A lncRNA TCL6-miR-155 Interaction Regulates the Src-Akt-EMT Network to Mediate Kidney Cancer Progression and Metastasis. Cancer Res. 2021;81:1500–1512. doi: 10.1158/0008-5472.CAN-20-0832. PubMed DOI PMC